Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

NCT05316246 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NK/T Cell Lymphoma Nos

Interventions

DRUG: Brentuximab Vedotin in Combination with Tislelizumab

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]